Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACMONO-XL trial of tacrolimus monotherapy versus standard triple immunosuppression in older kidney transplant recipients
2024-517709-10-00Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Aug 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus, mycophenolate mofetil and prednisone in kidney transplant (2 arms), sponsored by Erasmus MC. Primary endpoints: Death by infectious disease and Infectious burden. Planned start Aug 2025; status: authorised.
02
Drugs
tacrolimusmycophenolate mofetilprednisone
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2024-517709-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517709-10-00.